OBJECTIVES

: Both GIPAP ang VPAP terminate in December 31st, 2019 in Vietnam, that would affect on treatment accessibility of patients. This study aimed to analyze the budget impact of both programs termination within the next 5 years in Vietnam to assess the association between Health Insurance budget and the accessibility of patients.

METHODS

: Budget impact analysis method with models built to estimate the effect of Glivec and Tasigna for 5-year period from 2019 to 2023 in 7 hospitals which applied these two programs in Vietnam.

RESULTS

: While both programs existed in 2019, Health Insurance fund paid a total of 648.3 billion VND (488.8 billion VND for Glivec and 159.5 billion VND for Tasigna) and patients’ accessibility is 100.0%. Because of the termination of both programs, unchanged drug prices would reduce the payment of Health Insurance with 110.4 billion VND (94.4 billion VND for Glivec and 16.0 billion VND for Tasigna) and cause the lowest accessibility (10.4%). Considering a discount of 60% in drug prices, Health Insurance budget would increase each year in the period of 2020-2023 for both Glivec and Tasigna. With Health Insurance payment rate of 50%, Health Insurance budget would rise from 71.9 billion VND (in 2020) to 87.9 billion VND (in 2023), which would be lower than that in 2019. With payment rates of Health Insurance increasing from 50% to 100%, Health Insurance budget would go up and reach the peak at 100% with 535.1 billion VND (in 2020) and 656.4 billion VND (in 2023) for both drugs, which The accessibility rate of patients would also increase from 18.28% (in 50% payment) to 70.94% (in 100% payment).

CONCLUSIONS

: A 60% discount of drug prices would increase patients’ accessibility when GIPAP and VPAP terminate. In addition, the lower Health Insurance budget (due to lower payment rates), the greater patients’ accessibility.